The key ingredient in a controversial medicine used to prevent premature births is associated with a higher risk of cancer in people that were exposed to the treatment in utero, according to a new study.
Specifically, those exposed to 17-OHPC had nearly double the risk of any cancer compared to those not exposed, although the risk appeared to vary depending on the cancer. For instance, children exposed to 17-OHPC had more than 34 times greater risk of brain cancer, and as adults had more than five times greater risk of colorectal and prostate cancers.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
